title: Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study.
authors.forename: Claudio
authors.initials: C
authors.lastname: Ponticelli
authors.forename: Maurizio
authors.initials: M
authors.lastname: Salvadori
authors.forename: Maria Piera
authors.initials: MP
authors.lastname: Scolari
authors.forename: Franco
authors.initials: F
authors.lastname: Citterio
authors.forename: Paolo
authors.initials: P
authors.lastname: Rigotti
authors.forename: Antonella
authors.initials: A
authors.lastname: Veneziano
authors.forename: Marta
authors.initials: M
authors.lastname: Bartezaghi
mesh_terms: D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D000068338:Everolimus; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016030:Kidney Transplantation / Q000276:immunology; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000068338:Everolimus; D020123:Sirolimus